Evoke Pharma Pre-Tax Profit Margin 2012-2024 | EVOK
Evoke Pharma pre-tax profit margin from 2012 to 2024. Pre-tax profit margin can be defined as earnings before taxes as a portion of total revenue.
| Evoke Pharma Pre-Tax Profit Margin Historical Data |
| Date |
TTM Revenue |
TTM Pre-Tax Income |
Pre-Tax Margin |
| 2024-09-30 |
$0.01B |
$-0.01B |
-60.00% |
| 2024-06-30 |
$0.01B |
$-0.01B |
-77.78% |
| 2024-03-31 |
$0.01B |
$-0.01B |
-114.29% |
| 2023-12-31 |
$0.01B |
$-0.01B |
-133.33% |
| 2023-09-30 |
$0.01B |
$-0.01B |
-160.00% |
| 2023-06-30 |
$0.00B |
$-0.01B |
-200.00% |
| 2023-03-31 |
$0.00B |
$-0.01B |
-266.67% |
| 2022-12-31 |
$0.00B |
$-0.01B |
-400.00% |
| 2022-09-30 |
$0.00B |
$-0.01B |
-800.00% |
| 2022-06-30 |
$0.00B |
$-0.01B |
-800.00% |
| 2022-03-31 |
$0.00B |
$-0.01B |
-800.00% |
| 2021-12-31 |
$0.00B |
$-0.01B |
-900.00% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.007B |
$0.005B |
|
Evoke Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. The Company's lead product candidate, EVK-001, is in late stage clinical testing which is intended for the treatment of diabetic gastroparesis. Evoke Pharma, Inc. is based in San Diego, California.
|
